Investigating how hydroxychloroquine may prevent autoimmune diseases
Official title: Proteomic analysis of hydroxychloroquine prevention trials in T1D, RA and SLE
Funded at Benaroya Research Inst at Virginia Mason · NIH-11091902 · Data updated 2026-11-12
This study is looking at how the immune system works in people with early signs of autoimmune diseases and whether a medication called hydroxychloroquine can help stop these early signs from turning into serious conditions like type 1 diabetes or lupus, by analyzing blood samples from participants at different stages of their health.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Benaroya Research Inst at Virginia Mason NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 18, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $365,178 |
| NIH project number | 3U01AI176320-02S1 |
| Project ID | NIH-11091902 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals with a high risk of developing autoimmune diseases, particularly those with positive autoantibody tests.
✕Less likely to help
Patients who are already diagnosed with advanced autoimmune diseases may not benefit from this research.
What this research studies
This research focuses on understanding the immune mechanisms that lead to autoimmune diseases by analyzing serum samples from clinical trials. It specifically examines how hydroxychloroquine (HCQ) may help prevent the progression from sub-clinical autoimmunity, indicated by the presence of autoantibodies, to full-blown autoimmune diseases like type 1 diabetes, systemic lupus erythematosus, and rheumatoid arthritis. By profiling serum proteins from participants at different stages of their disease, the study aims to identify common features that could inform future treatments. The research utilizes advanced proteomic analysis techniques to gather comprehensive data on immune responses.
Why it matters
Potential benefit: If successful, this research could lead to improved prevention strategies for autoimmune diseases, potentially benefiting many patients at risk.
How similar studies have gone: Previous research has shown promise in using similar proteomic approaches to understand autoimmune diseases, indicating potential for success in this study.
Where this research is happening
-
Benaroya Research Inst at Virginia Mason
Seattle, United States Active
Researchers
- Principal investigator: Buckner, Jane Hoyt — Benaroya Research Inst at Virginia Mason
- Study coordinator: Buckner, Jane Hoyt
Related research
Other NIH-funded projects on the same topics.
-
T cells and the switch from pre-autoimmunity to autoimmune disease
A study following people at risk for type 1 diabetes and people with Down syndrome to understand how certain T cells may shift toward causing autoimmune disease.
-
Genetic and epigenetic control of T cell function in autoimmune disease
This grant aims to understand how genetic and epigenetic changes affect how T cells behave in autoimmune diseases to find ways to reduce harmful immune responses.
-
Immune Tolerance Network (ITN) for immune tolerance therapies across autoimmune and allergic diseases
A national network runs clinical trials to test new immune-tolerance therapies that could help people with autoimmune and allergic diseases.
-
Immune Tolerance Network for safer, more effective immune therapies
A nationwide network tests new immune therapies to help people with autoimmune diseases, allergies, and transplant patients reach better control of their immune system.
-
Immune tolerance research network for safer transplant and autoimmune therapies
A national effort tests new treatments that make the immune system tolerate transplanted organs and fight autoimmune and allergic diseases more safely.
-
Immune Tolerance Network for allergy, autoimmunity, and transplantation
A large NIH program tests new immune-tolerance therapies to help people with autoimmune diseases, allergies, and transplant patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.